Isolation and characterization of a highly attenuated respiratory syncytial virus (RSV) vaccine candidate by mutagenesis of the incompletely attenuated RSV A2 ts-1 NG-1 mutant virus

Author： Hsu K.-H.L.   Crowe J.E.   Lubeck M.D.   Davis A.R.   Hung P.P.   Chanock R.M.   Murphy B.R.  

Publisher： Elsevier

ISSN： 0264-410X

Source： Vaccine, Vol.13, Iss.5, 1995-01, pp. : 509-515

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Immunological properties of plaque purified strains of live attenuated respiratory syncytial virus (RSV) for human vaccine

By Herlocher M.L.   Ewasyshyn M.   Sambhara S.   Gharaee-Kermani M.   Cho D.   Lai J.   Klein M.   Maassab H.F.  

Vaccine, Vol. 17, Iss. 2, 1999-01 ,pp. : 172-181

Elsevier

Access to resources Recommend Favorite

The immunogenicity, protective efficacy and safety of BBG2Na, a subunit respiratory syncytial virus (RSV) vaccine candidate, against RSV-B

By Power U.F.   Plotnicky H.   Blaecke A.   Nguyen T.N.  

Vaccine, Vol. 22, Iss. 2, 2003-12 ,pp. : 168-176

Elsevier

Access to resources Recommend Favorite

Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization

By Crowe J.E.   Bui P.T.   Siber G.R.   Elkins W.R.   Chanock R.M.   Murphy B.R.  

Vaccine, Vol. 13, Iss. 9, 1995-06 ,pp. : 847-855

Elsevier

Access to resources Recommend Favorite

The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutations

By Juhasz K.   Whitehead S.S.   Boulanger C.A.   Firestone C.-Y.   Collins P.L.   Murphy B.R.  

Vaccine, Vol. 17, Iss. 11, 1999-03 ,pp. : 1416-1424

Elsevier

Access to resources Recommend Favorite

Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV) - A meeting report of the WHO Programme for Vaccine Development

By Crowe J.E.  

Vaccine, Vol. 13, Iss. 4, 1995-01 ,pp. : 415-421

Elsevier

Access to resources Recommend Favorite